Update: 200 common prescription medications increase depression risk

By SharpBrains | June 28, 2018

___ Dear read­er, Time for Sharp­Brains e‑newsletter. It’s been a busy month, once again bring­ing to the fore­front the lim­i­ta­tions of our cur­rent health­care sys­tem and, on the pos­i­tive side, the grow­ing oppor­tu­ni­ties to improve Brain Health and Men­tal Health for all, if we pay atten­tion to (and act on) lat­est research, think­ing and tools. New…

Read More

Sleep-focused neurotech firm Dreem raises $35M from Johnson&Johnson Innovation and Bpifrance

By SharpBrains | June 27, 2018

___ Dreem Announces $35 Mil­lion Financ­ing from lead investors John­son & John­son Inno­va­tion and Bpifrance (press release): “Dreem, a neu­rotech­nol­o­gy com­pa­ny, today announced the clos­ing of a new round of fund­ing, rais­ing $35 mil­lion USD to rapid­ly accel­er­ate prod­uct devel­op­ment, invest in strate­gic research and devel­op­ment, and advance the future of sleep tech­nol­o­gy. Last year,…

Read More

Neurotech start-up Rythm raises $11 million more to develop and commercialize sleep-monitoring headband Dreem

By SharpBrains | June 20, 2017

— Dreem machine: Rythm rais­es $11 mil­lion and launch­es $500 sleep-mon­i­­tor­ing head­band (Ven­ture­Beat) “Found­ed out of France in 2014, Rythm is now based in San Fran­cis­co, where it has been work­ing toward bring­ing its Dreem machine head­band to market…In a nut­shell, Rythm touts itself as a neu­rotech­nol­o­gy com­pa­ny that’s set­ting out to “enhance” your sleep, 

Read More